NCT06188520
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06188520
Title A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)
Acronym CYCAD-1
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | AUS

Facility Status City State Zip Country Details
Research Site St Louis Missouri 63141 United States Details
Research Site Providence Rhode Island 02903 United States Details
Research Site Nashville Tennessee 37201 United States Details
Research Site Houston Texas 77030 United States Details
Research Site East Melbourne 3002 Australia Details
Research Site Seoul 03722 South Korea Details
Research Site Seoul 06351 South Korea Details
Research Site Barcelona 8035 Spain Details
Research Site Pamplona 31005 Spain Details
Research Site Valencia 46010 Spain Details
Research Site Cambridge CB2 0XY United Kingdom Details
Research Site London EC1A 7BE United Kingdom Details
Research Site Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field